Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
December 3, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock Code: 600276 Stock abbreviation : Hengrui Pharma No.: Lin 2025-193

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement on the Resolution of the Twentieth Meeting of the Ninth Session of the Board of Directors

The board of directors (the "**Directors**") of the Company (the "**Board**") and all Directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") convened the twentieth meeting of the ninth session of the Board via teleconference on December 3, 2025. 11 Directors were required to attend this meeting, all 11 were present. The meeting was held in compliance with the Company Law of the People's Republic of China and the Articles of Association of the Company. All Directors carefully considered and approved the "Proposal on the Nomination and Appointment of the Senior Vice President of the Company".

In light of the Company's operational and development needs, Mr. Zhu Guoxin is hereby nominated and appointed as the senior vice president of the Company with a term commencing upon approval at this Board meeting and concluding upon the expiration of the term of the current session of the Board. The biographical details of Mr. Zhu are as follows:

Zhu Guoxin possesses over 30 years leadership experience in global multidisciplinary drug discovery, spanning all phases from target assumption to early clinical trials across multiple therapeutic areas, including diabetes/obesity and related complications, immunology, neurological disorders, pain, and oncology.

Prior to joining the Company, Zhu Guoxin served as the vice president of the center for research and development of novel drugs at Eli Lilly and Company ("**Eli**

Lilly"), where he led multiple drug discovery and research, as well as early stage development projects. As chairperson of the small molecule strategy group at Eli Lilly, he supervised the research and delivery of over 100 clinical small molecule drug candidates. He also served as a core member of the therapeutic area strategy group at Eli Lilly, contributing to investment portfolios and external research collaboration strategies across multiple therapeutic modalities (small molecules, peptides, antibodies, and siRNA).

Zhu Guoxin received his bachelor's degree at Zhejiang University, his master's and doctoral degrees at Shanghai Institute of Organic Chemistry, and completed postdoctoral research at Pennsylvania State University.

For: 11 votes Against: 0 votes Abstentions: 0 votes

This proposal had been considered and approved by the nomination committee of the Board.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

December 3, 2025